Is CAR-T covered by my Integrated Shield Plan in Singapore?

Check with your insurer. MediShield Life coverage for listed CTGTPs began in October 2025; private Integrated Shield Plan riders vary in whether and how they cover cell therapies, especially outside public institutions or overseas.

Can I use MediShield Life or MediSave for CAR-T therapy done in China?

No. MediShield Life and MediSave coverage applies to listed Cell, Tissue and Gene Therapy Products delivered at Singapore public healthcare institutions, not to treatment received overseas.

I'm a foreigner living in Singapore — what are my CAR-T options?

You can access CAR-T in Singapore at full list price, or evaluate accredited centres abroad. Because the price gap is large, obtaining a properly vetted overseas quote before deciding is usually worthwhile.

How do I find out my actual subsidised CAR-T price in Singapore?

Ask your public hospital's medical social worker for a means-tested financial counselling estimate. CTGTP subsidies are applied automatically based on your per-capita household income (PCHI) tier.

Insights · Singapore Guide

CAR-T Therapy in Singapore: Costs, Subsidies, and When Going Abroad Makes Sense

By the Lengdeh Team · Published 11 August 2026 · Last updated 11 August 2026 · 8 min read

A practical guide for Singaporean patients and families — what's approved here, what it really costs after subsidies, and how Singapore compares with China and the West.

In short: CAR-T cell therapy is now an established option in Singapore's public hospitals, with a reported full cost of about US$375,000 (S$481,000) before support. Since 2024–2025, the Government has layered on means-tested subsidies (up to 75%, capped at S$150,000), MediShield Life claims (up to S$150,000 per treatment course), and MediSave use. For eligible citizens on approved indications, out-of-pocket costs fall dramatically. But eligibility is narrow — higher-income households, permanent residents, patients outside the approved indications, and foreigners get little or nothing. That's where cross-border options such as China, at US$30,000–US$140,000 for the therapy itself, enter the conversation.

What is CAR-T therapy — in one minute

CAR-T (chimeric antigen receptor T-cell) therapy takes a patient's own immune T-cells, re-engineers them in a lab to recognise a marker on cancer cells, and infuses them back as a one-time "living drug". It is part of a broader family of treatments The Straits Times has described as using living cells to cure disease — a shift away from conventional chemotherapy toward therapies built from the patient's own biology.

For certain blood cancers that have relapsed or stopped responding to chemotherapy — B-cell acute lymphoblastic leukaemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL) among them — CAR-T can offer durable remission where little else can.

What's available in Singapore today

Singapore has moved faster than most of Asia on access:

Kymriah (tisagenlecleucel) — Singapore's first commercially approved CAR-T therapy, and in August 2024 the first product listed under MOH's Cell, Tissue and Gene Therapy Product (CTGTP) subsidy framework, for relapsed/refractory B-ALL and DLBCL.
Yescarta (axicabtagene ciloleucel) — added as the second subsidised CTGTP in September 2025, as second- or third-line treatment for relapsed/refractory DLBCL and high-grade B-cell lymphoma. As The Straits Times reported, MOH estimates 20–30 patients a year may benefit, out of roughly 300 DLBCL diagnoses annually.
Home-grown innovation — for T-cell leukaemia, which standard CAR-T does not address, a Singapore-developed CD7 CAR-T therapy at NUHS achieved complete remission in 16 of 17 relapsed/refractory patients treated on a compassionate basis — results The Straits Times covered as new hope for T-cell leukaemia that does not respond to conventional therapies.

Treatment is delivered at public institutions such as Singapore General Hospital and the National University Health System.

What CAR-T actually costs in Singapore

The sticker price is the headline problem. Yescarta's full cost in Singapore is about US$375,000 (S$481,000), per Straits Times reporting — before any subsidy.

Three layers of support now exist, as covered in the ST's report on government subsidies for cell, tissue and gene therapy:

Layer	What it gives	Who qualifies
CTGTP subsidy (from 2024)	Up to 75% off, capped at S$150,000 per course	Citizens, means-tested by per-capita household income (PCHI): 75% / 60% / 45% at rising PCHI tiers; 0% above S$11,400 PCHI. PRs: 22.5%, capped at S$45,000 (PCHI ≤ S$3,600)
MediShield Life (from Oct 2025)	Claims up to S$150,000 per treatment course	All citizens/PRs, for listed CTGTPs at public institutions — sized to fully cover about two in three subsidised patients
MediSave	Withdrawals toward the remaining balance	Per MOH limits

Subsidy tiers and caps per the Ministry of Health CTGTP subsidy framework; figures indicative and subject to change — confirm with your hospital's financial counsellor.

The realistic picture

Lower- and middle-income citizen, approved indication: the stack of subsidy + MediShield Life + MediSave can take up to S$300,000 off a ~S$480,000 therapy, with MediSave narrowing the rest.
Higher-income households (PCHI above S$11,400): no subsidy. MediShield Life's S$150,000 still helps, but the remaining ~S$300,000+ is largely private.
Permanent residents: 22.5% subsidy at best.
Outside the approved indications (cancers or lines of treatment not on the CTGTP list), or foreigners treated in Singapore: effectively full list price.

How Singapore compares globally

Market	Therapy list price	Public funding?	Typical wait
Singapore	~US$375,000 (S$481,000)	Yes — subsidies + MediShield Life for eligible citizens on listed indications	Weeks
China	US$30,000–US$140,000 (US$45,000–US$180,000 all-in)	Limited; largely self-pay	Days — cells manufactured in ~8 days
United States	US$275,000–US$475,000 (US$400,000–US$550,000+ all-in)	Insurance-dependent	Weeks to 2–3 months
United Kingdom	£280,000+ (~US$350,000)	NHS-funded for eligible patients	Weeks
Australia	AUD 500,000–1,000,000 private	Publicly funded for approved indications	Weeks

Regional figures from our full cost comparison guide.

Two things stand out. First, Singapore's list price sits in the same band as the US — this is not a cheap place to buy CAR-T at retail. Second, China's price floor is an order of magnitude lower, which is why the BBC World Service's Asia Specific has documented patients flying to China for treatment — including an Australian doctor who paid about AUD 110,000 in Shanghai against an estimated AUD 1 million pathway at home.

When going abroad makes sense for a Singaporean patient

Staying home is usually right when:

Your cancer matches a listed indication (r/r B-ALL, DLBCL, high-grade B-cell lymphoma) and you're a subsidised citizen — the financing stack makes Singapore one of the best-value CAR-T destinations anywhere, with world-class haematology teams and follow-up care minutes from home.
You may be eligible for a local trial or compassionate-use programme — such as the NUHS CD7 CAR-T work for T-cell leukaemia.

Looking abroad is worth serious evaluation when:

You're above the means-test threshold, a PR, or a foreigner, and facing S$300,000–S$480,000 out of pocket in Singapore against a US$45,000–US$180,000 all-in cost in China.
Your cancer or treatment line is not on the CTGTP list — for example indications where China has approved products or active trials (500+ CAR-T trials, 8 approved products) that Singapore does not yet cover.
Speed matters. Aggressive relapsed disease does not wait; Chinese centres report vein-to-vein times measured in days.

The risks of treatment abroad — centre quality, toxicity management (CRS and neurotoxicity), continuity of follow-up — are real and shouldn't be glossed over. We walk through them, and the vetting sequence we recommend, in Why Cancer Patients Are Flying to China for Treatment.

Frequently asked questions

Is CAR-T covered by my Integrated Shield Plan?: Check with your insurer. MediShield Life coverage for listed CTGTPs began in October 2025; private IP riders vary in whether and how they cover cell therapies, especially outside public institutions or overseas.
Can I use MediShield Life or MediSave for CAR-T done in China?: No. Coverage applies to listed CTGTPs delivered at Singapore public healthcare institutions.
I'm a foreigner living in Singapore — what are my options?: You can access CAR-T here at full list price, or evaluate accredited centres abroad. The price gap usually makes a properly vetted overseas quote worth obtaining before deciding.
How do I find out my actual subsidised price in Singapore?: Ask your public hospital's medical social worker for a means-tested financial counselling estimate — subsidies are applied automatically based on your PCHI tier.

Get a real number before you decide

Headline prices — in Singapore or anywhere else — are not quotes. If you're weighing a S$300,000+ out-of-pocket bill at home against treatment abroad, the only sound basis for the decision is a written, all-in quote from an accredited centre, reviewed against your actual diagnosis and prior lines of treatment. Lengdeh helps patients obtain and compare verified quotes, so the choice is made on facts rather than fear.

Talk to us

Sources

The Straits Times — Cell therapy: Using living cells to cure disease
The Straits Times — New treatment offers hope for T-cell leukaemia
The Straits Times — Government subsidies now available for cell, tissue and gene therapy
BBC World Service, Asia Specific — Why cancer patients are flying to China for treatment
Ministry of Health, Singapore — Subsidies for Cell, Tissue and Gene Therapy at public healthcare institutions
Singapore General Hospital — Second CTGTP for aggressive blood cancer now subsidised
NUS Medicine / N2CR — New CAR-T cell therapy for relapsed/refractory T-cell leukaemia
Novartis Singapore — Kymriah, Singapore's first commercially approved CAR-T therapy

This article is for general information only and is not medical or financial advice. Subsidy amounts, coverage limits and product listings change; verify current figures with MOH, your hospital's financial counsellor, and your insurer before making treatment decisions.